F-Prime
VC Fund
Cambridge, United States
F-Prime is a VC fund in Cambridge focused on Health Care and Biotechnology. F-Prime enables companies to turn their boldest ambitions into world-changing breakthroughs in life sciences, technology, healthtech + services, and crypto. Our legacy spans over 50 years, built on the belief that the best investors share the same entrepreneurial spirit of the founders they back—and that conviction still guides us today.Inhealthcare, we focus on therapeutics, medtech, and healthtech + services in a stage-agnostic fashion. In technology, we focus on enterprise software, fintech and frontier tech, and crypto. While we’re early-stage investors by choice, we’ll back exceptional teams at any stage.Today, our $4.8 billion under management support breakthroughs across healthcare and technology. Our seasoned team of scientists, engineers, physicians, operators, and investors bring real world expertise to help companies accelerate their path to scalable growth, always with an eye towards a shared vision—achieving something incredible.
- Total investments:
- 542
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries F-Prime invests in
Stages F-Prime invests in
Countries F-Prime invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 20 contacts → | |||
Round size
- Seed
- $1.6M–$20M
- Series A
- $8M–$87M
- Series B
- $15M–$112M
Investment Focus
Industry
- Health Care 125 (23%)
- Biotechnology 117 (22%)
- Medical 67 (12%)
- Therapeutics 49 (9%)
- Software 47 (9%)
Stage
- Series A 161 (30%)
- Series B 139 (26%)
- Seed 55 (10%)
- Series C 53 (10%)
- Venture - Series Unknown 30 (6%)
Country
- United States 215 (40%)
- China 19 (4%)
- United Kingdom 18 (3%)
- India 13 (2%)
- Japan 4 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alexander Pasteur
Partner
|
Partner | Total investments: 13 | Find email | |
Sanjay Aggarwal
Venture Partner
|
Venture Partner | Total investments: 15 | Find email | |
Shervin Ghaemmaghami
Operating Partner
|
Operating Partner | Total investments: 7 | Find email | |
Stacie Weninger
Executive Director
|
Executive Director | Total investments: 7 | Find email | |
Ben Gorman
Principal
|
Principal | Total investments: 5 | Find email | |
| See all 20 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Flourish Health is a medical center that treats high-acuity mental health conditions including PTSD, depressive, and serious mood disorders. | $26M / Series A / Jul 27, 2026 | ||
| Venice provides private, uncensored AI chat and image generation, with API and token-based access for developers and users. | $65M / Series A / Jul 01, 2026 | ||
| Pie is an AI technology company that provides an agentic growth platform for small businesses. Its platform automates local marketing by managing business visibility across Google Maps, Yelp, Nextdoor, and AI search platforms such as ChatGPT and Gemini. Pie also uses AI to optimize marketing performance in real time and handle customer phone calls,enabling business owners to focus on daily operations. | $19.5M / Series A / Jun 30, 2026 | ||
| Immuneel Therapeutics Pvt Ltd is a pioneering startup company leading the charge in cell therapy and personalized immunotherapy for patients | $10.5M / Series B / Jun 08, 2026 | ||
| Countable Labs provides a PCR system for single-molecule counting and high-sensitivity molecular detection in biotechnology. | $26M / Series A / May 28, 2026 | ||
| Fazeshift provides an AI-driven solution that automates invoicing, cash application, and collections for enterprises. The platform enhances cash flow management by streamlining accounts receivable processes and reducing errors. Fazeshift adapts to unique business challenges, offering customizable workflows to improve operational efficiency. | $17M / Series A / May 07, 2026 | ||
| Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M / Series A / Mar 24, 2026 | ||
| R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M / Series A / Mar 17, 2026 | ||
Almanac Health
|
Almanac Health is a clinical AI platform that brings specialist-grade knowledge to clinicians at the point of care, providing evidence-based clinical decision support across medical specialties, and governed by institutional controls. | $10M / Seed / Mar 16, 2026 | |
| Cyclops.io is a team of serial entrepreneurs with backgrounds from Cisco, Nuance, Bessemer Venture Partners, MIT, Caltech and Harvard. They have an extensive background in online video and collaboration, machine vision and deep learning. Their mission is to replicate the feeling and collaborative richness of being in the same room. It could be usedinternally by distributed teams or by sales or customer service with customers or partners. Everything should be as simple as a click. They are constantly looking for ways to improve your experience. Stay tuned for new and exciting features. | $8M / Seed / Mar 04, 2026 | ||
| See all 542 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does F-Prime invest in?
F-Prime invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 542 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is F-Prime's check size?
F-Prime typically joins rounds of $1.6M–$20M at Seed, $8M–$87M at Series A and $15M–$112M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds F-Prime participates in.
How do I contact F-Prime?
Public channels for F-Prime include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at F-Prime?
The team at F-Prime includes Alexander Pasteur (Partner), Sanjay Aggarwal (Venture Partner) and Shervin Ghaemmaghami (Operating Partner), among 20 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
